ovarian cancer
Conditions
Interventions
experimental group:This study is divided into a treatment phase and a maintenance phase. During the treatment phase, the initial dose of Herombopag Olamine is 5 mg once daily, taken 2 hours before mea
Sponsors
Fudan University Shanghai Cancer Center
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: Age =18 years; Thrombocytopenia induced by the use of PARPi Platelet count 20×10^9/L = PLT = 75×10^9/L, and still using PARPi within three days before enrollment No dose delays or adjustments for PARPi at the time of enrollment; Normal hematopoiesis, liver and kidney function; Exclusion of patients with decreased total blood cell count (hemoglobin <8.0gm/dL or ANC < 1000/uL); ECOG performance status: 0-2; Signed informed consent.
Exclusion criteria
Exclusion criteria: Previous use of TPO-RA drugs, excluding rh-TPO; Uncontrollable active infections; Subjects with radiation therapy and bone marrow infiltration; Individuals with bleeding tendencies, evidence of hereditary bleeding diathesis or coagulation disorders; Pregnant or lactating women, or female patients of childbearing potential not using contraception; Participation in another drug clinical trial within 4 weeks; Patients with uncontrollable neurological, psychiatric diseases or mental disorders, poor compliance, unable to cooperate or report treatment responses; Individuals allergic to the study drug.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Platelets; | — |
Secondary
| Measure | Time frame |
|---|---|
| The time required for PLT recovery; | — |
Countries
China
Contacts
Public ContactJu Xingzhu
Fudan University Shanghai Cancer Center
Outcome results
None listed